On Friday 28 June 2019, Saniona AB (publ) ("Saniona") announced the successful completion of a rights issue, issuing 3.7m new shares at a subscription price of SEK 18, resulting in gross proceeds of SEK 67m. The proceeds will enable Saniona to complete its ongoing Phase 2a studies with Tesomet for the treatment of Prader-Willi syndrome and hypothalamic obesity and initiate discussions with regulatory agencies for start of Phase 2b/3 studies in 2020, as well as to progress the Company’s other programs, internally or together with partners. In connection with the rights issue, Saniona engaged ABG Sundal Collier as sole financial advisor.
Saniona is a research and development company focused on drugs for diseases of the central nervous system and eating disorders. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION).